An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease

Bone Marrow Transplantation

Volumn 25, Issue 9, 2000, Pages 925-930

  Bolinger, A M ^a   Zangwill, A B ^a   Slattery, J T ^b,c   Glidden, D ^a   DeSantes, K ^d   Heyn, L ^a   Risler, L J ^c   Bostrom, B ^e   Cowan, M J ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Department of Orthopedics and Rehabilitation   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone marrow transplantation; Busulfan; Children; Cyclophosphamide; Toxicity

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; PHENYTOIN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; HURLER SYNDROME; INFANT; LEUKEMIA; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SIBLING; SICKLE CELL ANEMIA; STOMATITIS;

EID: 0034016713     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702371     Document Type: Article

References (21)

1. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat: relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Transplantation 1977; 24: 52-62.
2. Santos GW, Tutschka PJ. Marrow transplantation in the busulfan treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst 1974; 53: 1781-1785.
3. Peters WP, Henner WB, Growchow LB et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987; 47: 6402-6406.
4. Grochow LB, Krivit W, Whitley CB, Blazer BR. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
5. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
6. Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386-390.
7. Gibbs JP, Murray G, Risler L et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509-5516.
8. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-2479.
9. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
10. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060.
11. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
12. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
13. Growchow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18-25.
14. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
15. Slattery JT. Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20: 543-549.
16. Bearman SI, Applelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 562-568.
17. Agresti A. An Introduction to Categorical Data Analysis. Wiley: New York, 1996.
18. Cleveland WS. Robust locally weighted regression and smoothing scatter plots. J Am Stat Assoc 1979; 74: 829-836.
19. Regazzi MB, Locatelli F, Buggia I et al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther 1993; 53: 45-52.
20. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20: 915-920.
21. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.